Holen Sie sich die Stockscreener-App
7.31
7.12%
-0.56
Cero Therapeutics Holdings Inc Aktie (CERO) Neueste Nachrichten
CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements - TipRanks
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 - MSN
Trading Halted for CERO; Anticipated Announcement Pending | CERO Stock News - GuruFocus
Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance
CERO Announces One-for-Twenty Reverse Stock Split | CERO Stock N - GuruFocus
CERo Therapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com South Africa
CERo Therapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
CERo Therapeutics Announces Reverse Stock Split - TipRanks
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire
CERo Therapeutics Sets Major 1:20 Reverse Split, Shares Consolidate 95% Next Week - Stock Titan
CERo Therapeutics issues additional Series D stock By Investing.com - Investing.com South Africa
CERo Therapeutics Completes Series D Stock Issuance - TipRanks
CERO Expands Series D Preferred Stock Offering to Raise Capital - GuruFocus
CERo Therapeutics issues additional Series D stock - Investing.com
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million - Nasdaq
CERo Therapeutics Lands $3M Series D Extension as CAR-T Cancer Trial Shows Promise - Stock Titan
CERo Therapeutics regains Nasdaq compliance - MSN
Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance
CERo Therapeutics secures key patents for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Expands Leadership with New Executive Roles - TipRanks
Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) - Insider Monkey
CERO Therapeutics Expands Patent Portfolio with New U.S. and Eur - GuruFocus
CERo Therapeutics secures key patents for cancer therapy - Investing.com Australia
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 - The Globe and Mail
CERo Therapeutics Holds 18 Patents and Applications Expanding Immunotherapy Portfolio - Nasdaq
CERo Therapeutics Secures 18 Global Patents for Revolutionary Cancer-Fighting Cell Therapy Technology - Stock Titan
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial - MSN
CERo Therapeutics (NASDAQ:CERO) Rating Lowered to “Hold” at D Boral Capital - Defense World
CERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital - Defense World
CERo Therapeutics begins phase 1 trial for leukemia treatment By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.47 amid market challenges By Investing.com - Investing.com South Africa
CERO Initiates Phase 1 Trial for CER-1236 in Acute Myeloid Leuke - GuruFocus
Cero Therapeutics (CERO) Downgraded to Hold as Stock Faces Another Reverse Split | CERO Stock News - GuruFocus
CERO stock plunges to 52-week low at $0.47 amid market challenges - Investing.com Nigeria
CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com
CERO Stock Downgraded to Hold by D. Boral Capital | CERO Stock News - GuruFocus
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial - marketscreener.com
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations - The Manila Times
CERo Therapeutics Holdings, Inc. Doses First Patient with - GlobeNewswire
CERo Therapeutics Announces First Patient Dosed in Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia, to be Featured at ASCO 2025 - Nasdaq
First Patient Receives Revolutionary CAR-T Therapy in Groundbreaking Leukemia Clinical Trial - Stock Titan
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Benzinga
LI Earnings: Li Auto Delivers Q1 Beat but Guidance Disappoints - The Globe and Mail
Meet the Monster Quantum Computing Stock That Continues to Crush the Market - The Globe and Mail
CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at Maxim Group - Defense World
Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq
Maxim Group sets Cero Therapeutics stock with $3 target By Investing.com - Investing.com Nigeria
CERO Therapeutics (CERO) Receives 'Buy' Rating from Maxim Group | CERO Stock News - GuruFocus
Maxim Group sets Cero Therapeutics stock with $3 target - Investing.com
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):